17-year follow-up of association between telomere length and all-cause mortality, cardiovascular mortality in individuals with metabolic syndrome: results from the NHANES database prospective cohort study
-
Published:2023-12-02
Issue:1
Volume:15
Page:
-
ISSN:1758-5996
-
Container-title:Diabetology & Metabolic Syndrome
-
language:en
-
Short-container-title:Diabetol Metab Syndr
Author:
Xiong Lijiao,Yang Guangyan,Guo Tianting,Zeng Zhaohao,Liao Tingfeng,Li Yanchun,Li Ying,Chen Fujuan,Yang Shu,Kang Lin,Liang Zhen
Abstract
Abstract
Background
The relationship between leukocyte telomere length (LTL) and mortality risk in individuals with metabolic syndrome (MetS) remains poorly understood. This study aimed to investigate the association between telomere length and long-term all-cause mortality, and cardiovascular disease (CVD) mortality, in individuals with MetS in the United States.
Methods
A total of 1980 participants with MetS aged 18 years or older from the National Health and Nutrition Examination Survey (NHANES) prospective cohort study (1999–2002) were included in this cohort study. Medical records review was used to identify the cause of deaths as of December 2018. We employed Kaplan-Meier curves, fitted curves, and Cox proportional hazards regression models to estimate hazard ratios (HRs) for all-cause and CVD mortality, stratified by tertiles of LTL.
Results
Over a median follow-up of 17.75 years of participants with metabolic syndrome, 819 deaths occurred, including 231 cardiovascular deaths. After adjusting for multiple covariates, participants with shorter telomere length had a significantly higher risk of all-cause mortality (HR, 1.33; 95% CI, 1.11–1.6) and CVD mortality (HR, 1.36; 95% CI, 0.96–1.93) compared with those in the highest tertile of telomere length. All-cause mortality (P < 0.001) and cardiovascular disease mortality (P = 0.028) followed a similar pattern across tertiles of telomere length.
Conclusion
In individuals with MetS, shorter telomere length is associated with increased risks of death from cardiovascular disease and all causes. The underlying mechanisms and clinical implications of these findings require additional investigation.
Funder
administration of Traditional Chinese Medicine of Jiangxi Province, China the Science and Technology Planning Project of Shenzhen City, Guangdong Province, China
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference37 articles.
1. Pammer LM, Lamina C, Schultheiss UT, Kotsis F, Kollerits B, Stockmann H, Lipovsek J, Meiselbach H, Busch M, Eckardt KU, et al. Association of the metabolic syndrome with mortality and major adverse cardiac events: a large chronic Kidney Disease cohort. J INTERN MED. 2021;290(6):1219–32. 2. Kim TE, Kim H, Sung J, Kim DK, Lee MS, Han SW, Kim HJ, Kim SH, Ryu KH. The association between metabolic syndrome and Heart Failure in middle-aged male and female: Korean population-based study of 2 million individuals. Epidemiol Health. 2022;44:e2022078. 3. Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011–2016. JAMA. 2020;323(24):2526–8. 4. Mongraw-Chaffin M, Foster MC, Anderson C, Burke GL, Haq N, Kalyani RR, Ouyang P, Sibley CT, Tracy R, Woodward M, et al. Metabolically Healthy Obesity, transition to metabolic syndrome, and Cardiovascular Risk. J AM COLL CARDIOL. 2018;71(17):1857–65. 5. Li D, Wang L, Zhou Z, Song L, Chen S, Yang Y, Hu Y, Wang Y, Wu S, Tian Y. Lifetime risk of Cardiovascular Disease and life expectancy with and without Cardiovascular Disease according to changes in metabolic syndrome status. Nutr Metab Cardiovasc Dis. 2022;32(2):373–81.
|
|